OncoDNA
THE CANCER THERANOSTIC COMPANY

Nathalie **BERNARD**
Marketing Director

November 7th 2017

Helping cancer patients all over the world

From start-up to scale-up



> 20 000
ANALYSES SINCE 2014

> 230
HOSPITALS IN THE WORLD

> 50
COUNTRIES

20M €
FUND-RAISING

> 600
DRUGS DOCUMENTED

> 12 000
PEOPLE INSIDE ONCOSHARE

> 20 000
VARIANTS DOCUMENTED

> 50 000
CLINICAL TRIALS

OncoDNA
THE CANCER THERANOSTIC COMPANY

Product portfolio

OncoDEEP™ by OncoDNA

Cost-effective solution combining DNA and protein analysis of a solid tumour sample

More about OncoDEEP

OncoSTRAT&GO™ by OncoDNA

The complete solution integrating the analyses of solid and liquid biopsies

More about OncoSTRAT&GO

OncoTRACE™ by OncoDNA

Truly personalized monitoring solution from liquid biopsy sample

More about OncoTRACE

OncoSELECT™ by OncoDNA

Cancer-specific solution from a liquid biopsy sample

More about OncoSELECT

Assessing Immunotherapy response with 5 criteria



Included in our solid biopsy solutions

Represented by a personalised immunogram



From diagnostic

From diagnostic to SaaS

OncoKDM™



OncoDNA
THE CANCER THERANOSTIC COMPANY

DATA AND RESULTS

ONCOKDM INPUT OPTIONS

DATA CURRENTLY ACCEPTED:

- Technologies: Illumina, Ion Torrent, Sequenom
- DNA data from any cancer panel
- RNA data limited to fusion analysis
- ImmunoHistoChemistry data
- *Integrated soon : NanoString data and Cytoscan/SNP arrays*

DATA CURRENTLY NOT ACCEPTED :

- Whole Exome Sequencing (WES)
- Whole Transcriptome / RNA-Seq / Total RNA-Seq
- Germline data (associated with genetic disease)

WHAT ONCOKDM DELIVERS

ANALYSIS RESULTS:

- QC Analysis
- SNV, INDELS, CNV* (Copy Number Variants), MSI* (Microsatellite Instability). TMB* (Tumor Mutation Burden) detection
- Variant classification according to their biological impact
- Variant therapeutical impact per drug and cancer type

*If sufficient data is supplied by participant

COMPREHENSIVE REPORT:

- Interpretation and integration of all tumor data (NGS results and additional tests such as IHC, FISH, promotor methylation, ...) based on our proprietary knowledge database and algorithms
- Potentially beneficial treatments
- Eligibility for optional clinical trials
- Pathway visualization
- Pertinent scientific references
- Customized reporting (sharable and exportable as PDF)
- Statistical module in development (for internal studies or comparisons with public databases)

Moncodaneum Project

OncoDNA has received a grant of over $10M in support of the Moncodaneum Project.
This grant will cover the cost of interpreting and reporting on data for 50 cancer centers worldwide.

If you are interested in participating in this innovative project, please contact Dr. Jean-François Laes at jf.laes@oncodna.com !

OncoKDM™
Knowledge Driven Medicine

OncoDNA
THE CANCER THERANOSTIC COMPANY

OncoKDM Live Demo

Questions ?

Thank you!

Moncodaneum participation logistics

Phase I

1. Meeting with prospects to understand their needs
2. Establish a statement of work (that will include delivrables, milestones…)
3. Finalization and bilateral signature of the agreement of collaboration (Letter of Intent)

Phase II

1. Analysis of the different flows of data and integration of this flow into our pipelines
2. Retrospective analysis of a batch of samples (5) to compare our bioinformatics pipelines and the ones used on site
3. Virtual kick-off meeting to analyse the data and refine the customized OncoKDM
4. Starting of the in-routine process on a determined number of samples (10-15)

Moncodaneum participation logistics

Phase III

1. Face to face meetings to present the results on all the samples
2. Evaluation of opportunities of publications and writing of the papers if appropriate

Phase IV

1. Set up of the patient matching algorithm according to the panels / cancers / information collected
2. Evaluation of publications